Difference between revisions of "Team:Jilin China"

 
(55 intermediate revisions by 6 users not shown)
Line 28: Line 28:
  
 
<style>
 
<style>
 +
 +
/*This Part for Cleaning Default Template*/
 +
 +
#home_logo, #sideMenu { display:none; }
 +
html{width:100%;height:100%;background:white; list-style:none;}
 +
#globalWrapper,#HQ_page,#bodyContent,#mw-content-text{height:100%;}
 +
#sideMenu, #top_title, .patrollink  {display:none;}
 +
#content { margin-left:0px; margin-top:-7px; padding:0px; width:100%;height:100%;}
 +
body {background-color:white;height:100%;}
 +
#bodyContent h1, #bodyContent h2, #bodyContent h3, #bodyContent h4, #bodyContent h5 { margin-bottom: 0px; }
 +
 +
@font-face{
 +
  font-family: 'DIN B';
 +
  src: url('https://static.igem.org/mediawiki/2019/f/f5/T--Jilin_China--Home--Font--Medium.otf');
 +
  font-weight: normal;
 +
  font-size: normal;
 +
}
 +
 +
@font-face{
 +
  font-family: 'DIN B';
 +
  src: url('https://static.igem.org/mediawiki/2019/9/90/T--Jilin_China--Home--Font--Bold.otf');
 +
  font-weight: Bold;
 +
  font-size: normal;
 +
}
 +
 +
h1,h2,h3,h4,h5,p{
 +
  font-family:'DIN B','DIN Medium';
 +
}
 +
h1, h2, h3, h4, h5, h6{
 +
overflow:auto !important;
 +
padding: 1rem 0 !important;
 +
}
 +
p{
 +
margin:0 !important;
 +
}
 +
html,
 +
body,
 +
div,
 +
span,
 +
applet,
 +
object,
 +
iframe,
 +
h1,
 +
h2,
 +
h3,
 +
h4,
 +
h5,
 +
h6,
 +
p,
 +
blockquote,
 +
pre,
 +
a,
 +
abbr,
 +
acronym,
 +
address,
 +
big,
 +
cite,
 +
code,
 +
del,
 +
dfn,
 +
em,
 +
img,
 +
ins,
 +
kbd,
 +
q,
 +
s,
 +
samp,
 +
small,
 +
strike,
 +
strong,
 +
sub,
 +
sup,
 +
tt,
 +
var,
 +
b,
 +
u,
 +
i,
 +
center,
 +
dl,
 +
dt,
 +
dd,
 +
ol,
 +
ul,
 +
li,
 +
fieldset,
 +
form,
 +
label,
 +
legend,
 +
table,
 +
caption,
 +
tbody,
 +
tfoot,
 +
thead,
 +
tr,
 +
th,
 +
td,
 +
article,
 +
aside,
 +
canvas,
 +
details,
 +
embed,
 +
figure,
 +
figcaption,
 +
footer,
 +
header,
 +
hgroup,
 +
menu,
 +
nav,
 +
output,
 +
ruby,
 +
section,
 +
summary,
 +
time,
 +
mark,
 +
audio,
 +
video {
 +
 +
  border: 0;
 +
 +
}
 +
 +
 +
 +
 
  html{
 
  html{
 
  height: 100% !important;
 
  height: 100% !important;
Line 37: Line 161:
 
display:block !important;
 
display:block !important;
 
position:relative !important;
 
position:relative !important;
 +
overflow-x:hidden !important;
  
 
}
 
}
Line 72: Line 197:
  
 
}
 
}
 +
 +
.s1 p{
 +
float:left;
 +
}
 +
section{
 +
font-family: 'DIN Alternate';
 +
line-height: 150%;
 +
}
 +
 +
@media (min-width:1000px) {
 +
section{
 +
line-height: 200%;
 +
}
 +
 +
}
 +
  
  
Line 80: Line 221:
 
}
 
}
 
   p{
 
   p{
−
width: 90%;
+
width: 100%;
−
height: auto;
+
height: auto;1
 
margin: 0 auto;
 
margin: 0 auto;
 
position: relative;
 
position: relative;
Line 241: Line 382:
 
padding:3vw 7.5vw 6.5vw;
 
padding:3vw 7.5vw 6.5vw;
 
}
 
}
−
section h1{
+
section h1{
−
font-size: 2.8rem;
+
font-size: 2.8rem !important;
 
/*font-family: 'DIN Condensed';*/
 
/*font-family: 'DIN Condensed';*/
 
}
 
}
 
section h1.bg-white{
 
section h1.bg-white{
−
color: rgba(255,83,83,1);
+
color: rgba(255,83,83,1) !important;
 
}
 
}
 
section h2{
 
section h2{
−
font-size: 2rem;
+
font-size: 2rem !important;
 
/*font-family: 'DIN Condensed';*/
 
/*font-family: 'DIN Condensed';*/
 
}
 
}
 
 
 
section.left .text{
 
section.left .text{
−
float: left;
+
float: left !important;  
 
}
 
}
 
section.right .text{
 
section.right .text{
−
float: right;
+
float: right !important;
 
}
 
}
 
section.right .text *{
 
section.right .text *{
−
float: right;
+
float: right !important;
 
}
 
}
 
section.right .text h1{
 
section.right .text h1{
−
text-align: left;
+
text-align: left !important;
 
}
 
}
 +
  
 
.button:hover{
 
.button:hover{
Line 329: Line 471:
 
 
 
.symptom .digits .digit{
 
.symptom .digits .digit{
−
font-size:6.5vw;
+
font-size:5.5vw;
 
margin:0;
 
margin:0;
 
}
 
}
 
.symptom .digits .explain{
 
.symptom .digits .explain{
 
margin:0 0 3vw !important;  
 
margin:0 0 3vw !important;  
 +
                        border:0px;
 
}
 
}
 
 
Line 458: Line 601:
 
<h1 class="bg-white">What's VVC?</h1>
 
<h1 class="bg-white">What's VVC?</h1>
 
<p>Vulvovaginal candidiasis (VVC) has been recognized as one of the most common infections in female reproductive organs. </p>
 
<p>Vulvovaginal candidiasis (VVC) has been recognized as one of the most common infections in female reproductive organs. </p>
−
<p>VVC is mainly caused by Candida albicans (C. albicans), accounting for more than 85% of the incidence, which seriously affects the normal life of women.</p>
+
<p>VVC is mainly caused by <em>Candida albicans (C. albicans)</em>, accounting for more than 85% of the incidence, which seriously affects the normal life of women.</p>
 
</div>
 
</div>
 
<div class="clear"></div>
 
<div class="clear"></div>
Line 521: Line 664:
  
 
<div class="theraputic">
 
<div class="theraputic">
−
<h2>Theraputic System</h2>
+
<h2>Therapeutic System</h2>
 
<div>
 
<div>
−
<div class="effector1"><p>LL37 can perforate the cell membrane of C.albicans.</p><img alt="" src="https://static.igem.org/mediawiki/2019/2/2e/T--Jilin_China--Main--LL37.svg"/></div>
+
<div class="effector1"><p>LL-37 can perforate the cell membrane of C. albicans.</p><img alt="" src="https://static.igem.org/mediawiki/2019/2/2e/T--Jilin_China--Main--LL37.svg"/></div>
 
<div class="effector2"><p>The β-1,3-glucanase can disrupt the </br>biofilm of C. albicans.</p><img alt="" src="https://static.igem.org/mediawiki/2019/3/32/T--Jilin_China--Main--beta-1%EF%BC%8C3-glu.svg"/></div>
 
<div class="effector2"><p>The β-1,3-glucanase can disrupt the </br>biofilm of C. albicans.</p><img alt="" src="https://static.igem.org/mediawiki/2019/3/32/T--Jilin_China--Main--beta-1%EF%BC%8C3-glu.svg"/></div>
 
<div class="effector3"><p>BDSF can inhibit hypha formation </br>by C. albicans.</p><img alt="" src="https://static.igem.org/mediawiki/2019/e/ed/T--Jilin_China--Main--BDSF.svg"/></div>
 
<div class="effector3"><p>BDSF can inhibit hypha formation </br>by C. albicans.</p><img alt="" src="https://static.igem.org/mediawiki/2019/e/ed/T--Jilin_China--Main--BDSF.svg"/></div>
Line 543: Line 686:
 
<div class="third_s">
 
<div class="third_s">
 
   <div id="third_1">
 
   <div id="third_1">
−
 
+
<div style="padding: 7.5vw"><img src="https://static.igem.org/mediawiki/2019/b/bc/T--Jilin_China--HP--HP_Overview.svg" width="100%" style=" margin: 0 auto"></div>
−
  <div class="t1inb"><div class="t1nb0"><img class="yilei"  src="https://static.igem.org/mediawiki/2019/9/96/T--Jilin_China--Main--HP_Brain_Half.svg" width="60%" ></div><div class="t1nb1"><div class="t1nb11">Initially, we brainstormed to decide our project. We came up with three projects: General White Resistance, Vaginitis Treatment and Plant Resistance Improvement</div></div></div>
+
−
 
+
−
  <div class="t1inb "><div class="t1nb0"><img class="erlei" class="imgdo"  src="https://static.igem.org/mediawiki/2019/c/c7/T--Jilin_China--Main--HPwomen.svg" height="90%" ></div><div class="t1nb1 t1do"><div class="t1nb11">After attending the women's lecture, we decided to study the method of treating vaginitis and confirmed VVC through questionnaire collection.</div></div></div>
+
−
 
+
−
  <div class="t1inb"><div class="t1nb0"><img class="yilei"  src="https://static.igem.org/mediawiki/2019/3/3a/T--Jilin_China--Main--HP_Brain_Full.svg" width="60%" ></div><div class="t1nb1"><div class="t1nb11">After interviewing patients and doctors, we learned about the current problems in the treatment of VVC and brainstormed the project 1.0.</div></div></div>
+
−
 
+
−
  <div class="t1inb "><div class="t1nb0"><img class="sanlei aha"    src="https://static.igem.org/mediawiki/2019/5/5d/T--Jilin_China--Main--HP1.0.svg" width="45%" ></div><div class="t1nb1 t1do"><div class="t1nb11">After having brainstormed project 1.0.We interviewed professors give us suggestions to improve our project 1.0 and obtained project 2.0.</div></div></div>
+
−
 
+
−
  <div class="t1inb"><div class="t1nb0"><img class="sanlei"  src="https://static.igem.org/mediawiki/2019/7/72/T--Jilin_China--Main--HP2.0.svg" width="45%" ></div><div class="t1nb1"><div class="t1nb11"> We interviewed experts for a comprehensive assessment of our project. To make project practical, we interviewed ethical experts, pharmacies and pharmacies.</div></div></div>
+
−
  <div id="hparrow"><img  src="https://static.igem.org/mediawiki/2019/c/c7/T--Jilin_China--Main--HP_arrow.svg" width="130%"></div></div>
+
−
  </div>
+
 
   </div>
 
   </div>
 +
  
 
 
Line 611: Line 744:
 
<div id="result" class="botton otr"><p>Result</p><a class="foota otr1" href="https://2019.igem.org/Result"></a></div>
 
<div id="result" class="botton otr"><p>Result</p><a class="foota otr1" href="https://2019.igem.org/Result"></a></div>
  
−
<div id="par" class="botton otr"><p>Our Parts</p><a class="foota otr1" href="https://2019.igem.org/Team:Jilin_China/Parts"></a></div>
+
<div id="par" class="botton otr"><p>Parts</p><a class="foota otr1" href="https://2019.igem.org/Team:Jilin_China/Parts"></a></div>
  
 
<div id="hpp" class="botton otr"><p>Practices</p><a class="foota otr1" href="https://2019.igem.org/Team:Jilin_China/Human_Practices"></a></div>
 
<div id="hpp" class="botton otr"><p>Practices</p><a class="foota otr1" href="https://2019.igem.org/Team:Jilin_China/Human_Practices"></a></div>
Line 678: Line 811:
 
<script src="https://2019.igem.org/wiki/index.php?title=Template:Jilin_China/tool.js&action=raw&ctype=text/javascript"></script>
 
<script src="https://2019.igem.org/wiki/index.php?title=Template:Jilin_China/tool.js&action=raw&ctype=text/javascript"></script>
 
<script src="https://2019.igem.org/wiki/index.php?title=Template:Jilin_China/bubble.js&action=raw&ctype=text/javascript"></script>
 
<script src="https://2019.igem.org/wiki/index.php?title=Template:Jilin_China/bubble.js&action=raw&ctype=text/javascript"></script>
 +
<script type="text/javascript">
 +
 +
let configs = {
 +
colorStart: "#fff4e6",
 +
colorStop: "#ffe9e4",
 +
 +
compose: "source-over",
 +
bubbleFunc: () => `hsla(${Math.random() * 50}, 100%, 50%, .3)`,
 +
canvas: $$("maincabg")
 +
}
 +
  
 +
bubbly(configs);
 +
</script>
 
</html>
 
</html>
 +
{{:Team:Jilin_China/foot_Cont}}

Latest revision as of 03:32, 22 October 2019

Team
Project
Lab
Model
Parts
HP
Judging
Home
Members
Collaborations
Attributtions
Background
Description
Design
Result
Demonstrate
Notebook
Protocols
Safety
Model
Our parts
Improvement
Measurement
Integrated
Engagement
Juding Form
Medals

What's VVC?

Vulvovaginal candidiasis (VVC) has been recognized as one of the most common infections in female reproductive organs.

VVC is mainly caused by Candida albicans (C. albicans), accounting for more than 85% of the incidence, which seriously affects the normal life of women.

70-75%

of women will suffer from VVC at least once in thier life time.

40-45%

will have 2 or more episodes.

Symptoms

Abnormal Vaginal Discharge

Genital and Vaginal burning

External Dysuria

Itching and Redness

How to Treat?

Till now, as a commonly used antifungal drug for VVC treatment, vaginal azole preparations can inhibit the growth of C. albicans, or kill them directly.

HOWEVER

The widespread usage of antifungal drugs and the increase in the number of fungal infections have led to the emergence of drug resistance, even the repeated recurrence to VVC of patients.

Learn More about The Background

But, there is a

New Therapy for Vulvovaginal Candidasis:

Our Systems

Sensing System

Sensing system can sense C. albicans and activate the downstream gene.

Therapeutic System

LL-37 can perforate the cell membrane of C. albicans.

The β-1,3-glucanase can disrupt the
biofilm of C. albicans.

BDSF can inhibit hypha formation
by C. albicans.

Msp1 can destabilize the hyphae of C. albicans.

Learn More about Our Design

Practices Facilitated Our Project

Model

Our project is well conducted by Model in terms of experiments and prediction of future application. Our Model is constituted with

1. C. albicans Sensing Model
2. Gene Concentration Prediction Model
3. Market Prediction Model

Learn More about Our Model

In Case You Missed Them:

Background

Design

Result

Parts

Practices

Medals


CONTACT US
Jilin_China AT Outlook.com
Nation Engineering Labortory for
AIDS Vaccine
Comate Bioscience
Gen Script
TransGen Biotech
MathWorks
Jilin
University
School of Life Science
TAIMEI TECHNOLOGY
Git Hub
NEW ENGLAND BioLabs
Agilent
Technologies